Compare · ABOS vs ARGX
ABOS vs ARGX
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABOS and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $60.67B, about 3647.2x ABOS ($16.6M).
- ABOS has been more active in the news (11 items in the past 4 weeks vs 10 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 14 for ABOS).
- Company
- Acumen Pharmaceuticals Inc.
- argenx SE
- Price
- -
- -
- Market cap
- $16.6M
- $60.67B
- 1M return
- -
- +21.82%
- 1Y return
- -
- +9.90%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2017
- News (4w)
- 11
- 10
- Recent ratings
- 14
- 25
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ABOS
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits
- Acumen Pharmaceuticals downgraded by BofA Securities with a new price target
- Acumen Pharmaceuticals downgraded by Stifel with a new price target
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
- SEC Form EFFECT filed by Acumen Pharmaceuticals Inc.
- SEC Form S-3 filed by Acumen Pharmaceuticals Inc.
- SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.
- SEC Form 8-K filed by Acumen Pharmaceuticals Inc.
- Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Latest ARGX
- SEC Form 6-K filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
- Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
- Amendment: SEC Form SCHEDULE 13G/A filed by argenx SE
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
- SEC Form 6-K filed by argenx SE